The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Open accessAbstract
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All these effects are consistent with reported roles of APOE4 in inflammation, synaptic impairment, MAPK1 signaling and downstream APP transcription, and early endosomes7,18.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is associated with increased amyloid-β deposition, hyperphosphorylation and aggregation of tau, and accelerated cognitive decline4–7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE4 polymorphism alters the accessibility of the lipid-binding region, which interferes with its cholesterol and lipid transport capacity7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“having the APOE ɛ4 coding mutation(s) increases AD risk 3–15 fold [3]”
From Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include PLCG2 P522R rare variant (rs72824905) that provides robust protection against AD (odds ratio ≈ 0.68 [1, 4], comparable to having one APOE2 allele [5]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE is the most important risk factor for AD and contributes significantly to the risk of developing several other neurological and nonneurological disorders (18).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the APOE-E4 allele confers a ∼ 3.7 times greater risk than the common variant, APOE-E3, whereas homozygous APOE-E4/E4 carriers have a ∼12-15 times greater risk for developing AD.”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE genotype is the strongest genetic risk factor for AD21, with APOE ε2 conferring protection from disease and APOE ε4 conferring higher risk, compared to the APOE ε3 allele”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, binding to LDLR is required by ApoE to perform its downstream effector function (50–52).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE gene is a known genetic risk factor for neurodegeneration and cardiovascular disease (CVD) [1, 2].”
From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 exacerbates amyloid pathology by promoting Aβ production and aggregation, and inhibiting Aβ clearance and degradation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 aggravates the tau pathology via promoting tau phosphorylation, aggregation, propagation, and tau-mediated neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 isoform may affects the development and progression of AD through multiple different pathways in which inflammatory regulation plays crucial role.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperphosphorylated forms of the microtubule-associated protein tau in neurons is a major hallmark of AD [2, 3].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple cohort studies have demonstrated that the APOE ε4 allele is a major genetic risk factor for AD”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“while the three common isoforms (APOE2, APOE3, and APOE4) influence both amyloid‐β–dependent and independent pathways implicated in AD pathogenesis [1, 2].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aβ and tau.43,44”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Cerebrovascular dysfunction has been recognized as a major pathological process of AD”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
The cited source says what the claim attributes to it.
In the citing paper
“with ApoE4-positive cells showing reduced function (Rawat et al., 2019; Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 shows both loss-of-function and gain-of-toxic-function across various AD pathogenesis pathways (Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, cerebral glucose hypometabolism occurs in both the early stage of AD (Christian et al., 2020; Yamazaki et al., 2019) and epilepsy (McDonald et al., 2018; Patel, 2018).”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Yamazaki et al., 2019
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“We also found that LECs isolated from the meninges of 6-month-old 5xFAD mice showed significant changes in the expression of genes involved in processes such as exocytosis, phospholipase D signaling, and response to low-density lipoprotein (Extended Data Fig. 1f–k), suggesting that meningeal Aβ deposition might affect meningeal LECs early on through deleterious processes previously implicated in”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a specific ApoE4 fragment, ApoE4[Δ(166-299)], has previously been found to promote the cellular uptake of extracellular Aβ42 and resulted in increased oxidative stress [28], similar to the effect of L28P.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“APOE is the most significant known risk factor for sporadic Alzheimer’s disease”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“ApoE4 exhibits the strongest receptor binding and is considered a high-risk allele, while ApoE2 exhibits the weakest receptor binding and is considered protective (Yamazaki et al., 2019).”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“APOE also affects tau pathogenesis and tau-mediated neurodegeneration [468].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [468]
In the citing paper
“In fact, 39 AD-associated genes were found within the 10th percentile of highly expressed genes in meningeal LECs, including Apoe, which is intrinsically linked to altered risk for late onset AD15,31 and was one of the few highly expressed genes found at the intersection between all three cell types (Extended Data Fig. 9o).”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,006
NHE6-Depletion Corrects ApoE4-Mediated Synaptic Impairments and Reduces Amyloid Plaque LoadPreprint
Pohlkamp, T., Xian, X., Wong, C. H. Y., Durakoglugil, M. S., Werthmann, G. C., Saido, T., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.22.436385 · Cited by 4
Sharma, S., Wahl, D., Risen, S. J., Gilberto, V. S., Chatterjee, A., Moreno, J. A., LaRocca, T. J., & Nagpal, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.07.583991 · Cited by 4
WITHDRAWN: Border-associated macrophages in the central nervous system
Sun, R., & Jiang, H. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.109921 · Cited by 4
RetractedMaladies neurodégénératives et stress oxydant
Lévy, E. (2020) · theses.fr (ABES) · doi:10.70675/75371581z194fz4cb4zb457z91bf72dc0320 · Cited by 4
Kroll, F., Donnelly, J., Özcan, G. G., Mackay, E., & Rihel, J. (2025) · eLife · doi:10.7554/elife.96839.3 · Cited by 3
The associations of cerebrospinal fluid ApoE and C1q with Alzheimer's disease biomarkers
Lin, Y.-J., Liu, Y., Sheng, Z.-H., Fu, Y., Ma, L.-Z., Zhang, Z.-H., Wang, L.-Y., Huang, L.-Y., Liu, M., Wang, Z.-T., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251320419 · Cited by 3
C‐reactive protein‐mediated dementia
Tang, J., Lu, Q., Lin, H., Li, J., Zhu, X., & Ma, T. (2025) · Psychogeriatrics · doi:10.1111/psyg.70032 · Cited by 3
Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 3
de Soto, J. G., Castro‐Mosquera, M., Pouso-Diz, J. M., Cabrera, A. F., Rodríguez‐Arrizabalaga, M., Debasa‐Mouce, M., Camino-Castiñeiras, J., Pereiro, A. M. M., Aramburu-Núñez, M., Romaus‐Sanjurjo, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157068 · Cited by 4
Hoidy, W. H., Essa, S. M., & Al-Saadi, A. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70214 · Cited by 3
Petre, A. M., Thieschafer, J. S., Palsuledesai, C. C., Cornille, K., Chang, A., Li, L., & Distefano, M. D. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00320 · Cited by 3
Petek, B., Mo, M., Xu, H., Norgren, J., Hoang, M. T., Villa‐Lopez, M., Häbel, H., Kele, J., Naia, L., Maioli, S., et al. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251385903 · Cited by 3
Vilor‐Tejedor, N., Rodrigo, A., Genius, P., Rodríguez‐Fernández, B., Anastasi, F., Pelkmans, W., Navarro, A., Adams, H. H. H., Wisse, L. E. M., Gispert, J. D., et al. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103889 · Cited by 3
Abnormal behaviors and glial responses in an animal model of tau pathology
Liu, Y., Sobue, A., Sahara, N., Isobe, M., Tanaka, R., Zhu, Y., Zhu, W., Matsuzaki, T., Yamanaka, K., Yamada, K., et al. (2025) · Molecular Brain · doi:10.1186/s13041-025-01252-4 · Cited by 3
Lehodey, A., Montagne, B., Rehel, S., Kaliman, P., Chocat, A., Mézenge, F., Landeau, B., Sayette, V. D. L., Chételat, G., Rauchs, G., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01923-3 · Cited by 3
Batista, A. F., Presumey, J., Singh, B. B., Yalçın, E., Schroeder, M. K., Khan, K., Spooner, E., Li, S. A., Carroll, M. C., & Lemere, C. A. (2025) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00010-z · Cited by 3
Ihoeghian, N. A., Abbas, U. L., Imam, I. A., & Shao, Q. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp03829d · Cited by 3
Jiraanont, P., Wang, J. Y., Durbin-Johnson, B., Hwang, Y. H., Hessl, D. R., Rivera, S. M., Hagerman, R. J., & Tassone, F. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107292 · Cited by 3
Li, F., Chen, Y., Western, D., Ali, M., Liu, M., Gong, K., Xu, Y., Lowery, J., Holtzman, D. M., Robins, C., et al. (2026) · Advanced Science · doi:10.1002/advs.202513872 · Cited by 5
Morovati, A., Moussa, Y., Kalupahana, N. S., Zu, Y., Jun, H., Fokar, M., & Moustaïd‐Moussa, N. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101407 · Cited by 3
Microglial Neurotransmitter Receptors in Health and Disease
Bi, Q., Guo, C., Chen, N., Zhou, X., Zhou, Q., Liu, X., Shen, X. Z., & Shi, P. D. (2026) · Physiology · doi:10.1152/physiol.00030.2025 · Cited by 3
Alzheimer’s Disease: From Pathogenesis to Emerging Therapeutic Targets
Takahashi, T., & Muguruma, K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062357 · Cited by 3
APP as an innate injury-response molecule
Olmsted, Z. T., & Sofroniew, M. V. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107361 · Cited by 3
Lai, L., Tang, Y., Song, G., Long, Y., Chen, C., Chen, C., & Li, W. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03064-2 · Cited by 3
Elevated levels of circulating plasma sPDGFRβ in cognitively impaired APOE4 carriers
Sagare, A. P., Lohman, T., Ramirez, I., Joe, E., Harrington, M. G., Chui, H. C., Schneider, L. S. S., Yassine, H. N., Ringman, J. M., Toga, A. W., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02291-y · Cited by 3
Management of Alzheimer’s Disease with nutraceuticals
Yadav, J. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820593-8.00028-8 · Cited by 3
The biphasic impact of apolipoprotein E ε4 allele on age-related hearing loss
Han, J. S., Yoo, S. G., Lee, S. J., Lee, H. J., Choi, I. Y., & Park, K. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-71774-9 · Cited by 3
Moseholm, K. F., Meineche, J. T., & Jensen, M. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000968 · Cited by 3
Wu, H., Gu, X., Liu, S., Wang, P., Lü, H., Guan, Y., Shi, Z., & Ji, Y. (2025) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70045 · Cited by 3
Gao, X., Yin, Y., Chen, Y., Lu, L., Zhao, J., Xu, L., Wu, J., Li, Q., & Zeng, R. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100763 · Cited by 3
The causal association between resting state intrinsic functional networks and neurodegeneration
Nassan, M. M., Daghlas, I., Diamond, B. R., Martersteck, A., & Rogalski, E. J. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf098 · Cited by 3
Underestimated virus impaired cognition-more evidence and more work to do
Awan, M. U. N., Mahmood, F., Peng, X.-B., Zheng, F., & Xu, J. L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550179 · Cited by 3
Cheng, F., Fransson, L., & Mani, K. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70162 · Cited by 3
Ji, Y., Jiang, J., Hu, L., Peng, L., Zhou, M., Hu, S., Wang, M., Ji, Y., Liu, X., Yan, D., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01155-y · Cited by 3
Apolipoprotein E Alleles and Motor Signs in Older Adults with Alzheimer’s Dementia
Liampas, I., Demiri, S., Siokas, V., Tsika, A., Marogianni, C., Stamati, P., Nasios, G., Messinis, L., Lyketsos, C. G., & Dardiotis, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178562 · Cited by 3
Apolipoprotein E polymorphism carriers exhibit objective cognitive deficits: a single center trial
Zeng, Y., Huang, X., Elkin, K. B., Stone, C., Rajah, G. B., Guan, L., Du, H., & Geng, X. (2020) · Neurological Research · doi:10.1080/01616412.2020.1782130 · Cited by 3
He, H., Lu, H., Liu, S., Cai, J., Tang, X. A., Mo, C., Xu, X., Chen, Q., Xu, M., Nong, C., et al. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02522-2 · Cited by 3
Amer, M. S., Hamza, S. A., Shaltoot, H. M. H., Zaki, O. K., Saad, W. E., Saab, A. A. E.-R., & Abdelrahman, E. E. (2021) · Egyptian journal of Immunology · doi:10.55133/eji.28.01.01 · Cited by 3
Rohn, T. T., Beck, J. D., Galla, S. J., Isho, N. F., Pollock, T. B., Suresh, T., Kulkarni, A., Sanghal, T., & Hayden, E. J. (2021) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710020 · Cited by 3
Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
Patel, K., Srivastava, S., Kushwah, S., & Mani, A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210027 · Cited by 4
Halla, S. B., Tazzite, A., Gazzaz, B., Moutawakil, B. E., & Dehbi, H. (2022) · Gene Reports · doi:10.1016/j.genrep.2021.101484 · Cited by 3
Quantitative glycoproteomics of high-density lipoproteins
Tang, X., Wong, M., Tena, J., Zhu, C., Rhodes, C., Zhou, Q., Vinjamuri, A., Oloumi, A., Boddu, S., Luxardi, G., et al. (2022) · RSC Advances · doi:10.1039/d2ra02294j · Cited by 3
Manganese level and cognitive decline in older adults with the APOE e4 allele: a preliminary study
Kim, S. G., Choe, Y. M., Suh, G., Lee, B. C., Choi, I.-G., Kim, H. S., Hwang, J., Keum, M., Yi, D., & Kim, J. W. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115403 · Cited by 3
Gothwal, A., Lamptey, R. N. L., Trivedi, R., Chaulagain, B., & Singh, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613019 · Cited by 3
Pizzonia, K. L., Suhr, J. A., Clark, L. A., & Clark, B. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206473 · Cited by 3
Kumar, H. S., Moore, J. M., Steiner, A. C., Sotirakis, E., Schärli, B., Isnard, P., Thiam, K., Wolfer, D. P., & Böttger, E. C. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05031-z · Cited by 3
Cao, T. H. M., Le, A. P. H., Tran, T. T., Huynh, V. K., Pham, B. H., Le, T., Nguyen, Q. L., Tran, T. C., Tong, T. M., Than, T. H. N., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1308610 · Cited by 3
Sadhukhan, D., Mishra, S., Mukherjee, P., Biswas, A., Hui, S. P., Banerjee, T. K., & Biswas, A. (2023) · Austin Alzheimer s and Parkinson s Disease · doi:10.26420/austinalzheimersjparkinsonsdis.2023.1040 · Cited by 3
Pratt, J., Via, J. D., Sale, C., Gebre, A. K., Stephan, B. C. M., Laws, S. M., Zhu, K., Lim, W. H., Prince, R. L., Lewis, J. R., et al. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae134 · Cited by 3
Chaves, J. C. S., Milton, L. A., Stewart, R., Senapati, T., Rantanen, L. M., Wasielewska, J. M., Lee, S., Hernández, D., McInnes, L. E., Quek, H., et al. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10127-9 · Cited by 3
Meng, F., & Zhang, X. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.129 · Cited by 4
Theoretical Aspects of Protein Aggregation and Neurodegenerative Diseases
Singh, V. K., & Dey, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006957 · Cited by 3
Egln3 expression in microglia enhances the neuroinflammatory responses in Alzheimer’s disease
Guan, J., Wu, P., Liu, M., Jiang, C., Meng, X., Wu, X., Lu, M., Fan, Y., & Gan, L. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.12.022 · Cited by 3
Zhang, Z., Chen, Y., Wang, C., Guo, M., Cai, L., He, J., Liang, Y., Wong, G., & Chen, L. (2025) · Informatics · doi:10.3390/informatics12030068 · Cited by 3
Müller Glial Kir4.1 Channel Dysfunction in APOE4 ‐ KI Model of Alzheimer's Disease
Abhyankar, S. D., Xiao, Y., Mahajan, N. S., Luo, Q., Cummins, T., Oblak, A. L., Lamb, B. T., Corson, T. W., & Bhatwadekar, A. D. (2026) · Glia · doi:10.1002/glia.70119 · Cited by 3
Best, J. G., & Werring, D. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-70761-3_7 · Cited by 3
Killing ageing neurons, one cell at a time
Wagner, J., & Neher, J. J. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00855-z · Cited by 3
Wang, D., Ling, Y., Harris, K., Schulz, P. E., Jiang, X., & Kim, Y. (2023) · medRxiv · doi:10.1101/2023.10.27.23297685 · Cited by 3
Editorial: APOE4-associated heterogeneity in the pathogenesis of Alzheimer's disease
Torres, E. R. S., Rebeck, G. W., & Nuriel, T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1509307 · Cited by 3
Yang, R., Li, Y., Zhao, X., Wang, L., Wu, J., & Sima, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.08.663694 · Cited by 3
Pinals, R. L., Islam, R., King, O., Choi, A., Kang, E., Nakano, M., Tuyeras, A., Naomi, M. T., Ngo, A., Jiang, A. Y. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678918 · Cited by 3
Georgiadou, D., & Chroni, A. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149644 · Cited by 2
XGBoost for Interpretable Alzheimer’s Decision Support
Kadem, M., Noseworthy, M., & Doyle, T. (2023) · Proceedings of the AAAI Symposium Series · doi:10.1609/aaaiss.v1i1.27491 · Cited by 2
Zhao, S., Liu, M., Chen, J., Meng, L., & Wang, Y. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116969 · Cited by 2
Jiang, L., Sun, X., Xie, Y., Dān, W., Xia, Y., & Xu, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135392 · Cited by 2
RetractedAPOE contributes to longitudinal impulse control disorders progression in Parkinson’s disease
Chen, L., He, X., Mao, L., & Liu, P. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06084-5 · Cited by 2
Moseholm, K. F., Jensen, M. K., Bůžková, P., Aroner, S. A., Fitzpatrick, A. L., Longstreth, W. T., López, O. L., Siscovick, D. S., Kizer, J. R., Ix, J. H., et al. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.01.009 · Cited by 2
Li, M., Wang, Y., Kazis, L. E., & Xia, W. (2025) · Brain Sciences · doi:10.3390/brainsci15050434 · Cited by 2
Chen, J., Chan, L., Hong, C., Hu, C. J., & Hsieh, Y. (2025) · Aging · doi:10.18632/aging.206248 · Cited by 2
Lwere, K., Muwonge, H., Sendagire, H., Sajatovic, M., Gumukiriza-Onoria, J. L., Buwembo, D., Buwembo, W., Nassanga, R., Nakimbugwe, R., Nazziwa, A., et al. (2025) · Medicine · doi:10.1097/md.0000000000042407 · Cited by 2
Li, L., Wang, W., Li, W., Chen, Y., Mao, Y., Li, Y., & Qiu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-08958-4 · Cited by 2
Dai, Y., Bi, M., Jiao, Q., Du, X., Chen, X., Yan, C., & Jiang, H. F. (2025) · Movement Disorders · doi:10.1002/mds.30294 · Cited by 2
Moravveji, S., Sadia, H., Doyon, N., & Duchesne, S. (2025) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2025.1590968 · Cited by 2
The Immunologic Underpinnings of Post-Stroke Depression
Sørensen, N. V., Hougaard, A., Kruuse, C. R., & Benros, M. E. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100575 · Cited by 2
Precision therapeutics for Alzheimer’s disease
Priyanka, S., Manjari, T., Hemalatha, S., Ambika, S., Yilmaz, B. N., Aktürk, B., Arısan, E. D., Kumari, A., & Manojkumar, Y. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.011 · Cited by 2
Feng, S., Que, J., Wang, Q., Yuan, K., & Shi, L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1627774 · Cited by 2
PRTS: Predicting Single-Cell Spatial Transcriptomic Maps from Histological Images
Wen, J., Zou, L., Liu, J., Guo, X., Liu, C., Wang, B., Deng, T., Liu, C., Tang, R., Yang, Y., et al. (2025) · Research · doi:10.34133/research.0961 · Cited by 2
Self-citationJin, T., Yang, H., Liu, F., Lin, S., Hu, J., Wang, J., & Gou, Y. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70224 · Cited by 2
Lost in Space and Thought: Navigating the Cognitive Map in Alzheimer’s Disease
Zhao, B., Zhou, S., Wei, T., Xu, J., Geng, C., Wang, Z., & Tang, Y. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01541-x · Cited by 2
Chen, J., Zhang, X., Chen, X., Yu, W., Jia, M., Zhu, L., Liu, Z., & Hu, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099591 · Cited by 2
Relationship periodontitis and Alzheimer's disease: Relevant aspects from an epigenetic view
Chacón, T., & Hernández, H. G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251397406 · Cited by 2
Zheng, Z., Tang, Z., Li, C., Xiao, H., Li, Y., He, A., Mao, Y., Zheng, J., Ke, M., Gao, R., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202519440 · Cited by 2
Self-citationHou, X., Richardson, T., Heckman, M. G., Fiesel, F. C., White, L. J., Koga, S., Ross, O. A., Dickson, D. W., & Springer, W. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02964-6 · Cited by 2
Dixon, P., & Anderson, E. L. (2025) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-025-00684-y · Cited by 2
MM-GHiNet: A multimodal graph hierarchical network for brain disease diagnosis
Li, C., Xu, J., Huang, Z., & Deng, L. (2026) · Expert Systems with Applications · doi:10.1016/j.eswa.2026.131202 · Cited by 2
Castellani, R. J., Bharadwaj, R. A., Fisher‐Hubbard, A., Deep‐Soboslay, A., Hyde, T. M., Kleinman, J. E., Hazrati, L., & Iverson, G. L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251411332 · Cited by 2
Koo, B. G., Seo, H., Yun, Y., Kim, D., Kang, J. M., Cho, J., Lee, S.-Y., Lee, Y. J., Park, K. H., Lee, M. J., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01994-w · Cited by 2
Burdman, G., Akkaoui, J., Colon, N., Perez, A. G., & Lakshmana, M. K. (2026) · Neurology International · doi:10.3390/neurolint18030050 · Cited by 2
Wang, R., Feng, Y., Zhou, Z., Jiang, J., Zhang, R., Zou, W., Yang, H., Lv, W., & Shen, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1748418 · Cited by 2
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
Kozlitina, J., Romeo, S., & Hobbs, H. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001758 · Cited by 2
wang, K., Yang, X., Magwood, G., Xu, C. D., Navia, R. O., Neils‐Strunjas, J., & Li, X. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48050442 · Cited by 2
Melrose, J. (2026) · Journal of Neuroscience Research · doi:10.1002/jnr.70151 · Cited by 2
APOE*ε4 is linked to BBB breakdown
Wood, H. B. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0367-x · Cited by 2
Aging, Dementia, and Alzheimer Disease
Sontheimer, H. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821228-8.00004-4 · Cited by 2
Fanelli, G., Franke, B., Witte, W. D., Ruisch, I. H., Haavik, J., van Gils, V., Jansen, W. J., Vos, S. J. B., Lind, L., Buitelaar, J. K., et al. (2022) · Yearbook of pediatric endocrinology · doi:10.1530/ey.19.12.4 · Cited by 2
Comprehensive behavioral study of C57BL/6.KOR-ApoEshl mice
Ueno, H., Takahashi, Y., Murakami, S., Wani, K., Miyazaki, T., Matsumoto, Y., Okamoto, M., & Ishihara, T. (2023) · Translational Neuroscience · doi:10.1515/tnsci-2022-0284 · Cited by 2
Santos, C. B., Santos, B. D. C., Reis, A. R., & Pires, L. V. (2024) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2024.200249 · Cited by 2
Is it time for a paradigm shift? Inclusion of APOE on genetic dyslipidemia panels
Ison, H. E., Mowaswes, M., Durst, R. Y., Leucker, T. M., Knowles, J. W., & Brown, E. E. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1889 · Cited by 2
Efficacy and Safety of Stem Cell Therapy in Alzheimer's Disease: A Review
Arora, D., Gupta, D., Deeksha, Taneja, Y., & Dhingra, A. K. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x267673231120061600 · Cited by 2
Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk
Cohen, C. E., Fernandez, S., Yaman, U., Ehyaei, A. R., Kodosaki, E., Askarova, A., Porter, T., O’Brien, E., Study, A. I. B. A. L., Initiative, A. D. N., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02036-1 · Cited by 1
Metadata
- Authors
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Bu, Guojun
- Venue
- Nature Reviews Neurology
- Published
- 2019-07-31
- Volume
- 15
- Issue
- 9
- Pages
- 501-518
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7055192
- OpenAlex
- W2965401191
- Cited by
- 1,425
- References
- 318
- Citations by year
- 2026: 191 · 2025: 259 · 2024: 233 · 2023: 242 · 2022: 200 · 2021: 172 · 2020: 124 · 2019: 4
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG051504, R01AG027924, R37AG027924, RF1AG057181, RF1AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, APOE polymorphism, amyloid-beta, tau pathology, neurodegeneration, microglial activation, lipid transport, synaptic plasticity, glucose metabolism, cerebrovascular function, precision medicine
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Humans, Polymorphism, Genetic, Amyloid beta-Peptides, Genetic Predisposition to Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
